Medifast, Inc. Announces Significant Cooperation Agreement with Steamboat Capital Partners – Key Details for Investors

Summary of the Announcement

Medifast, Inc. (NYSE: MED), a leading company in the health and wellness sector, has entered into a material Cooperation Agreement with Steamboat Capital Partners and its affiliated investment funds (collectively, the “Steamboat Group”). This agreement, announced on March 20, 2026, follows Steamboat Group’s disclosure of beneficial ownership of 657,590 shares of Medifast’s common stock, and is designed to address the composition of Medifast’s Board of Directors at the upcoming 2026 Annual Meeting of Stockholders.

Key Points for Investors

• Board Composition and Nominees: As part of the agreement, Medifast will include the nominees agreed upon with Steamboat Group (the “Agreed Nominees”) in its slate for election to the Board at the 2026 Annual Meeting. The company will recommend these nominees to shareholders and solicit votes in their favor.
• Steamboat’s Voting Commitments: Steamboat Group has agreed not to nominate alternative directors or submit any shareholder proposals at the 2026 Annual Meeting. They will vote all their shares in favor of the Agreed Nominees, the ratification of RSM US LLP as the independent auditor, the Board’s “say-on-pay” proposal, an amendment to the Company’s 2012 Share Incentive Plan to increase share reserves, and in line with the Board’s recommendations on other matters—except for significant “Permitted Matters” such as amendments that could diminish shareholder rights or Extraordinary Transactions (e.g., mergers, acquisitions, restructurings, or asset sales), on which they may vote at their discretion.
• Standstill and Non-Disparagement Provisions: The agreement contains robust standstill provisions. For the defined “Restricted Period” (lasting until several months after the 2027 Annual Meeting), Steamboat and its affiliates are restricted from:
  • Soliciting proxies or written consents from shareholders,
  • Engaging in or assisting with any other proxy contest or “referendum”,
  • Forming, joining, or participating in any group (as defined by Section 13(d) of the Exchange Act) with respect to Medifast’s voting securities, except among themselves,
  • Presenting proposals or nominations at shareholder meetings,
  • Granting proxies except for “Permitted Matters”, or
  • Taking any action that would require public disclosure of such activities by Medifast.

  Both parties are also subject to mutual non-disparagement obligations.

• Confidentiality and Director Conduct: Any Agreed Nominee serving as director must comply with all company policies, confidentiality agreements, and complete all required director documentation. Information may only be privately disclosed to certain Steamboat representatives under strict confidentiality.
• Press Release and Public Disclosure: The parties have agreed on a joint press release announcing the major terms of the agreement. The company clarified that the information is being furnished, not filed, and is not subject to liability under Section 18 of the Exchange Act.
• Expenses: Each party will bear its own costs related to the negotiation and execution of this agreement.
• Legal and Governance Provisions: The agreement is governed by Delaware law and contains typical enforcement, severability, and notice provisions. The Steamboat Group is required to ensure its affiliates and associates comply with the agreement.

Potential Share Price Impact and Shareholder Considerations

• Board and Governance Changes: The addition of new director nominees backed by a significant shareholder (Steamboat Group) could influence Medifast’s strategic direction, governance, and capital allocation. Such changes are frequently price-sensitive as they may signal shifts in company policy, priorities, or openness to strategic actions (including M&A or activist proposals in the future).
• Standstill Provisions: The agreement minimizes the risk of a public proxy contest or activist campaign through the 2027 annual meeting, which may be seen as stabilizing in the short term, but could also limit upside from activist-driven strategic shifts or buyout speculation.
• Extraordinary Transactions: The carve-out for voting at Steamboat’s discretion on major corporate actions (such as mergers or amendments that affect shareholder rights) means the group could still play a pivotal role in any significant transaction. Investors should monitor for any signs of strategic activity, as the presence of a large, engaged shareholder can be a catalyst for future events.
• Ongoing Dialogue: The cooperation could enhance communication between management and shareholders, though it also signals that significant shareholders are seeking a greater voice in Medifast’s direction.
• Shareholding Disclosure: Steamboat Group beneficially owns 657,590 shares as of the agreement date, which is a substantial holding and indicates continued interest in Medifast’s performance and governance.

Contact Information

Media Contact: Jessica Oring, [email protected]
Investor Contact: Steven Zenker, [email protected]

Forward-Looking Statements

This article contains forward-looking statements, including those relating to Medifast’s board composition, company strategy, and potential future transactions. These statements are subject to various risks and uncertainties, including those described in Medifast’s filings with the SEC. Actual results may differ materially from those anticipated. Investors should review all relevant filings and consider all risk factors before making any investment decisions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making investment decisions related to Medifast, Inc.

View MEDIFAST INC Historical chart here